DK1429780T3 - Fremgangsmåde til behandling af mellemoreinfektioner - Google Patents

Fremgangsmåde til behandling af mellemoreinfektioner

Info

Publication number
DK1429780T3
DK1429780T3 DK02799587T DK02799587T DK1429780T3 DK 1429780 T3 DK1429780 T3 DK 1429780T3 DK 02799587 T DK02799587 T DK 02799587T DK 02799587 T DK02799587 T DK 02799587T DK 1429780 T3 DK1429780 T3 DK 1429780T3
Authority
DK
Denmark
Prior art keywords
middle ear
ear infections
treating middle
treating
infections
Prior art date
Application number
DK02799587T
Other languages
Danish (da)
English (en)
Inventor
Michael G Wall
Peter J Conroy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23261416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1429780(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of DK1429780T3 publication Critical patent/DK1429780T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02799587T 2001-09-21 2002-09-13 Fremgangsmåde til behandling af mellemoreinfektioner DK1429780T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32395101P 2001-09-21 2001-09-21

Publications (1)

Publication Number Publication Date
DK1429780T3 true DK1429780T3 (da) 2006-02-13

Family

ID=23261416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02799587T DK1429780T3 (da) 2001-09-21 2002-09-13 Fremgangsmåde til behandling af mellemoreinfektioner

Country Status (19)

Country Link
US (8) US20030139382A1 (pl)
EP (1) EP1429780B1 (pl)
JP (1) JP2005504804A (pl)
KR (1) KR20040035760A (pl)
CN (1) CN1231218C (pl)
AT (1) ATE313328T1 (pl)
AU (1) AU2002333671B2 (pl)
BR (1) BR0212898A (pl)
CA (1) CA2459930C (pl)
CY (1) CY1104988T1 (pl)
DE (1) DE60208216T2 (pl)
DK (1) DK1429780T3 (pl)
ES (1) ES2250739T3 (pl)
FR (1) FR13C0012I2 (pl)
MX (1) MXPA04002576A (pl)
PL (1) PL212457B1 (pl)
RU (1) RU2295346C2 (pl)
WO (1) WO2003026671A1 (pl)
ZA (1) ZA200401847B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504804A (ja) * 2001-09-21 2005-02-17 アルコン，インコーポレイテッド 中耳感染を処置する方法
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
MX2007001811A (es) * 2004-08-13 2007-03-26 Schering Plough Ltd Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticoesteroide.
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US20080139545A1 (en) * 2006-05-22 2008-06-12 Won-Taek Choe Formulation to treat ear infection
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US20090263345A1 (en) * 2008-01-28 2009-10-22 Foresight Biotherapeutics, Inc. Otic compositions for the treatment of infections of the internal and external ear in mammals
KR101477329B1 (ko) 2008-05-14 2014-12-29 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
WO2009152374A2 (en) 2008-06-12 2009-12-17 Medtronic Xomed, Inc. Method for treating chronic wounds
MX2011000862A (es) * 2008-07-21 2011-03-15 Otonomy Inc Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos.
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2346324A4 (en) * 2008-10-06 2012-10-10 Microbial Defense Systems Llc ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
BRPI1008920A2 (pt) * 2009-03-03 2015-08-25 Alcon Res Ltd Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
WO2010143186A1 (en) * 2009-06-08 2010-12-16 Otic Pharma Ltd. Otic foam formulations
EP3508197A1 (en) * 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
EP2706845B1 (en) 2011-05-10 2021-06-23 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
ES2658995T3 (es) 2012-12-26 2018-03-13 Otic Pharma Ltd. Composiciones farmacéuticas óticas espumables
CN105682742A (zh) 2013-08-27 2016-06-15 奥德纳米有限公司 小儿耳部病症的治疗
US20150119371A1 (en) * 2013-10-30 2015-04-30 Micro Labs Limited Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents
AU2015284048A1 (en) 2014-07-03 2017-02-16 Otonomy, Inc. Sterilization of ciprofloxacin composition
US9393243B1 (en) * 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
US11040004B2 (en) 2016-09-16 2021-06-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134718A (en) * 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US5223493A (en) * 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
AU4201189A (en) * 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
WO1993005816A1 (en) * 1991-09-17 1993-04-01 Alcon Laboratories, Inc. Compositions containing quinolone antibiotics and sulfonate of polystyrol
ES2065846B1 (es) 1993-04-20 1995-10-01 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
ES2078175B1 (es) 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
WO1996039146A1 (en) 1995-06-06 1996-12-12 Bayer Corporation Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
JP2002525326A (ja) 1998-09-30 2002-08-13 アルコン ラボラトリーズ，インコーポレイテッド 眼、耳および鼻治療用の抗生物質組成物
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
JP2003510263A (ja) * 1999-09-24 2003-03-18 アルコン，インコーポレイテッド シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物
JP2005504804A (ja) * 2001-09-21 2005-02-17 アルコン，インコーポレイテッド 中耳感染を処置する方法

Also Published As

Publication number Publication date
US20090156566A1 (en) 2009-06-18
CA2459930C (en) 2009-11-10
DE60208216D1 (de) 2006-01-26
US9402805B1 (en) 2016-08-02
ATE313328T1 (de) 2006-01-15
AU2002333671B2 (en) 2006-07-20
KR20040035760A (ko) 2004-04-29
FR13C0012I1 (pl) 2013-04-05
US9345714B2 (en) 2016-05-24
ZA200401847B (en) 2005-05-25
US20150374716A1 (en) 2015-12-31
JP2005504804A (ja) 2005-02-17
RU2295346C2 (ru) 2007-03-20
BR0212898A (pt) 2004-10-13
US20160243029A1 (en) 2016-08-25
FR13C0012I2 (fr) 2014-02-14
US20160361324A1 (en) 2016-12-15
US9149486B2 (en) 2015-10-06
CN1231218C (zh) 2005-12-14
CA2459930A1 (en) 2003-04-03
EP1429780B1 (en) 2005-12-21
PL212457B1 (pl) 2012-10-31
CN1555267A (zh) 2004-12-15
MXPA04002576A (es) 2004-06-18
US20050059674A1 (en) 2005-03-17
RU2004111984A (ru) 2005-02-27
ES2250739T3 (es) 2006-04-16
PL369205A1 (pl) 2005-04-18
WO2003026671A1 (en) 2003-04-03
CY1104988T1 (el) 2009-11-04
EP1429780A1 (en) 2004-06-23
US20140363511A1 (en) 2014-12-11
US20030139382A1 (en) 2003-07-24
US20080214513A1 (en) 2008-09-04
DE60208216T2 (de) 2006-06-29
US8846650B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
DK1429780T3 (da) Fremgangsmåde til behandling af mellemoreinfektioner
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
NO20034056D0 (no) Proliferative sykdommer
ATE342097T1 (de) Elektroaktive pore
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DE60215494D1 (de) Bicyclische, stickstoffhaltige heterocyclische derivate zur verwendung als antibakterielle mittel
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
BR0107691A (pt) Sapogeninas substituìdas e seu uso
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1107780T1 (el) Μεθοδος για τη θεραπεια οφθαλμικων νεοαγγειακων ασθενειων
NO20015969D0 (no) Forbedret sklerittprotese for behandling av presbyopi og andre öyesykdommer
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
DK1441761T3 (da) Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
AR034713A1 (es) Composiciones para eliminar el cerumen humano
CY1106409T1 (el) Παραγωγα κινολινης
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
PT1140080E (pt) Utilizacao de riluzole no tratamento de traumatismos acusticos
DE60134885D1 (de) Antiangiogene polypeptide
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
EP3915593A3 (en) Ultraviolet light sanitizer
PT1169026E (pt) Utilizacao de activadores de ap-1 no tratamento do glaucoma e da hipertensao ocular